Mednet Logo
SpecialtiesRheumatology
Rheumatology

Rheumatology

Clinical discussions on autoimmune diseases, biologic therapies, vasculitis, and musculoskeletal conditions.

Recent Discussions

In light of promising results of hydroxychloroquine in COVID-19, should we consider using it prophylactically in cancer patients, especially if immunocompromised?

2
1 Answers

Mednet Member
Mednet Member
Rheumatology · MD Anderson Cancer Center

At this time, as there is no good evidence available, I would not recommend the use of hydroxycholoroquine prophylactically in cancer patients. It is unclear whether it would prevent contagion, probably not, and we still don't know if it will have any effect on the course of COVID-19. We expect ther...

Would you start hydroxychloroquine (or another DMARD) in a mid-20s female patient with positive ANA, SSA, SSB, and dsDNA, whose only clinical manifestation is intermittent parotid gland swelling?

1
6 Answers

Mednet Member
Mednet Member
Rheumatology · U.S. Department of Veterans Affairs

Hmm... I think the better question to ask is, do you code as Sjogren's lupus overlap to get way more medication options? Certainly, HCQ is a reasonable DMARD and a place to start for both diseases. I would code as lupus and Sjogren's to have more options for the future. Hope someone can weigh in on ...

In the treatment of osteoarthritis with low-dose radiation therapy is there data to support the claim that LDRT does not limit or preclude later orthopedic surgery?

6
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Baylor Scott & White Health

At LDRT doses, the biological effects are anti-inflammatory and immunomodulatory rather than cytotoxic or fibrogenic, and there is no evidence of vascular injury, impaired cellular proliferation, or tissue destruction. Animal models and cellular studies provide robust evidence that LDRT at OA releva...

How long after initiation of steroids and immunosuppressive therapy does muscle biopsy remain reliably informative in the setting of suspected inflammatory myopathy?

1 Answers

Mednet Member
Mednet Member
Rheumatology · University of Pittsburg

I don't think there is any definitive, well-validated answer here. Certainly, obtaining a biopsy within ~2 weeks of initiating therapy, in my experience, has clearly not affected the histopathologic findings that would be characteristic of dermatomyositis, necrotizing myopathy or autoantibody-associ...

Do you recommend allopurinol desensitization in gout patients who develop a rash on allopurinol therapy?

1
2 Answers

Mednet Member
Mednet Member
Rheumatology · National institues of Health

I don't recommend desensitization for allopurinol-allergic patients. There was a time when this made sense due to the lack of a viable alternative therapy. The process is cumbersome in a private practice setting and not as simple as providing the patient with a prescription for febuxostat.Febuxostat...

Are there particular subsets of AAV patients in which avacopan is more effective?

1 Answers

Mednet Member
Mednet Member
Rheumatology · Director, Vasculitis Clinical Research Consortium

The following answer was jointly drafted by Dr. Peter Merkel and Dr. David Jayne:Patients in the ADVOCATE trial were stratified at entry according to time of diagnosis (new/relapsing), diagnosis (GPA/MPA), ANCA serotype (PR3/MPO), and background immunosuppressive (cyclophosphamide/rituximab) with re...

How do you interpret treatment response in the DISCOVER-2 Trial when patients were allowed to remain on up to 10mg of prednisone equivalent for disease control while on guselkumab?

3 Answers

Mednet Member
Mednet Member
Rheumatology · Leiden University Medical Center

The dependence on the use of systemic glucocorticoids may indeed be a good reason to change treatment. Especially in patients with psoriatic arthritis. So, if patients are unable to stop systemic glucocorticoids and there are still treatment options for the patient, this could be tried. It is diffic...

Do you screen for cardiac disease in patients with dermatomyositis in the absence of symptoms?

1 Answers

Mednet Member
Mednet Member
Rheumatology · HSS

I don't typically evaluate for cardiac disease in patients with dermatomyositis who are not symptomatic. There are subtypes of myositis patients where cardiac involvement is more common (such as those with antimitochondrial antibodies and anti-SRP antibodies), and there it may make sense to keep a c...

How would you define failure of anabolic therapy for severe osteoporosis and when would you consider ordering a second round of Evenity or PTH analogue therapy?

2 Answers

Mednet Member
Mednet Member
Rheumatology · U of AZ Phoenix Dept of Orthopaedics

“Failure” of any therapy is often in the eyes of the beholder. The most efficient way to determine if there is anabolic activity is to measure a serum PINP (does not need fasting) and, for the PTH anabolic recheck, the PINP 2-3 months later. IF the delta is >10, you can be confident there is more pr...

How do you approach anticoagulation in a woman with SLE who is planning pregnancy, has persistently positive isolated anticardiolipin IgA and anti-β2 glycoprotein I IgA antibodies and a prior history of a provoked DVT after prolonged air travel?

2 Answers

Mednet Member
Mednet Member
Rheumatology · SUNY Upstate Medical University

I consider persistently positive IgA anticardiolipin and anti-β2 glycoprotein antibodies just as relevant as IgG/IgM subclasses. Moreover, phosphatidylserine antibodies are also relevant, if this patient could be tested for that as well.